Ruchi Desai, MD
Hematology · Richmond, VANPI 1710307517
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,729 of the $9,114 with a category attached, or 73.8%. Sanofi accounts for 78.9% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2024 at $4,382 and has fallen 96.0% since, to $175 in 2025.
Across 29 payments — averaging $314.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$7K
- Karyopharm Therapeutics Inc.$542
- Sobi, Inc$258
- AstraZeneca$233
- Blueprint Medicines Corporation$180
- Bristol Myers Squibb$175
- plus $531 from 7 others
Across 143 payments — averaging $1653.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Karyopharm Therapeutics Inc.$91K
- Blueprint Medicines Corporation$72K
- Bristol Myers Squibb$36K
- Sanofi US Services Inc.$21K
- E.r. Squibb & Sons, L.L.C.$13K
- Merck$4K
What the payments were for
- Speaking & faculty fees$6,72974%
- Travel & lodging$4675%
- Food & beverage$1,89821%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 9 | $7,194 |
| Karyopharm Therapeutics Inc. | 5 | $542 |
| Sobi, Inc | 3 | $258 |
| AstraZeneca | 2 | $233 |
| Blueprint Medicines Corporation | 2 | $180 |
| Bristol Myers Squibb | 1 | $175 |
| AbbVie | 1 | $119 |
| Genentech USA, Inc. | 1 | $117 |
| Dova Pharmaceuticals | 1 | $115 |
| Pfizer | 1 | $99 |
| Regeneron | 1 | $47 |
| E.r. Squibb & Sons, L.L.C. | 1 | $21 |
| Geron Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,114 in reported general payments places this provider in the 65th percentile of 26 hematology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| AyvakitAvapritinib | 29 | $1,105,081 |
| IdhifaEnasidenib Mesylate | 13 | $450,763 |
| CalquenceAcalabrutinib Maleate | 24 | $357,729 |
| SprycelDasatinib | 11 | $230,869 |
| PromactaEltrombopag Olamine | 11 | $61,260 |
| Cromolyn Sodium | 11 | $5,075 |
| Hydroxyurea | 36 | $1,055 |
| Duloxetine Hcl | 11 | $201 |
| Ondansetron Hcl | 11 | $62 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Blueprint Medicines CorporationAyvakit | $180 | $1,105,08129 claims |
| Bristol Myers SquibbIdhifa | $175 | $450,76313 claims |
| AstraZenecaCalquence | $233 | $357,72924 claims |
| E.r. Squibb & Sons, L.L.C.Sprycel | $21 | $230,86911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 26 hematology providers in Virginia.
Other hematology in Richmond
- Robert GlasserRichmond$74
- Carolina MartinRichmond$70
- Niru NaharRichmond$69
- Beatriz Caceres NazarioRichmond$33
- Alden ChesneyRichmond$19
- Yasmin LutterbieRichmond$14
- Hillary MaitlandCharlottesville$440K
- Barbara MacikCharlottesville$90K
- Emily AyersCharlottesville$63K
- Stephen MedlinFairfax$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.